SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Roffi Marco) "

Sökning: WFRF:(Roffi Marco)

  • Resultat 1-10 av 19
  • [1]2Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  • Chieffo, Alaide, et al. (författare)
  • Performing elective cardiac invasive procedures during the COVID-19 outbreak : a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
  • 2021
  • Ingår i: EuroIntervention. - : Europa Digital & Publishing. - 1774-024X .- 1969-6213. ; 16:14, s. 1177-1186
  • Tidskriftsartikel (refereegranskat)abstract
    • The rearrangement of healthcare services required to face the coronavirus disease 2019 (COVID-19) pandemic led to a drastic reduction in elective cardiac invasive procedures. We are already facing a "second wave" of infections and we might be dealing during the next months with a "third wave" and subsequently new waves. Therefore, during the different waves of the COVID-19 pandemic we have to face the problems of how to perform elective cardiac invasive procedures in non-COVID patients and which patients/procedures should be prioritised. In this context, the interplay between the pandemic stage, the availability of healthcare resources and the priority of specific cardiac disorders is crucial. Clear pathways for "hot" or presumed "hot" patients and "cold" patients are mandatory in each hospital. Depending on the local testing capacity and intensity of transmission in the area, healthcare facilities may test patients for SARS-CoV-2 infection before the interventional procedure, regardless of risk assessment for COVID-19. Pre-hospital testing should always be conducted in the presence of symptoms suggestive of SARS-CoV-2 infection. In cases of confirmed or suspected COVID-19 positive patients, full personal protective equipment using FFP 2/N95 masks, eye protection, gowning and gloves is indicated during cardiac interventions for healthcare workers. When patients have tested negative for COVID-19, medical masks may be sufficient. Indeed, individual patients should themselves wear medical masks during cardiac interventions and outpatient visits.
  •  
7.
  • Frigoli, Enrico, et al. (författare)
  • Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study
  • 2019
  • Ingår i: American Heart Journal. - : MOSBY-ELSEVIER. - 0002-8703 .- 1097-6744. ; 209, s. 97-105
  • Tidskriftsartikel (refereegranskat)abstract
    • Background The optimal duration of antiplatelet therapy in high-bleeding risk (HBR) patients with coronary artery disease treated with newer-generation drug-eluting bioresorbable polymer-coated stents remains unclear. Design MASTER DAPT (clinicaltrial.gov NCT03023020) is an investigator-initiated, open-label, multicenter, randomized controlled trial comparing an abbreviated versus a standard duration of antiplatelet therapy after bioresorbable polymer-coated Ultimaster (TANSEI) sirolimus-eluting stent implantation in approximately 4,300 HBR patients recruited from >= 100 interventional cardiology centers globally. After a mandatory 30-day dual-antiplatelet therapy (DAPT) run-in phase, patients are randomized to (a) a single antiplatelet regimen until study completion or up to 5 months in patients with clinically indicated oral anticoagulation (experimental 1-month DAPT group) or (b) continue DAPT for at least 5 months in patients without or 2 in patients with concomitant indication to oral anticoagulation, followed by a single antiplatelet regimen (standard antipkitelet regimen). With a final sample size of 4,300 patients, this study is powered to assess the noninferiority of the abbreviated antiplatelet regimen with respect to the net adverse clinical and major adverse cardiac and cerebral events composite end points and if satisfied for the superiority of abbreviated as compared to standard antiplatelet therapy duration in terms of major or clinically relevant nonmajor bleeding. Study end points will be adjudicated by a blinded Clinical Events Committee. Conclusions The MASTER DAPT study is the first randomized controlled trial aiming at ascertaining the optimal duration of antiplatelet therapy in HBR patients treated with sirolimus-eluting bioresorbable polymer-coated stent implantation.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 19
  • [1]2Nästa
Typ av publikation
tidskriftsartikel (19)
Typ av innehåll
refereegranskat (18)
övrigt vetenskapligt (1)
Författare/redaktör
Roffi, Marco (19)
Bueno, Héctor (12)
Windecker, Stephan (12)
Collet, Jean-Philipp ... (11)
Valgimigli, Marco (9)
Kolh, Philippe (7)
visa fler...
Kastrati, Adnan (7)
Neumann, Franz-Josef (7)
Agewall, Stefan (6)
Zamorano, Jose Luis (6)
Jüni, Peter (6)
Björck, Martin (5)
Ricco, Jean-Baptiste (5)
Aboyans, Victor (5)
Brodmann, Marianne (5)
Czerny, Martin (5)
De Carlo, Marco (5)
Tendera, Michal (5)
Vlachopoulos, Charal ... (5)
Widimsky, Petr (5)
Montalescot, Gilles (5)
Espinola-Klein, Chri ... (4)
Kahan, Thomas (4)
Kownator, Serge (4)
Mazzolai, Lucia (4)
Sprynger, Muriel (4)
Tepe, Gunnar (4)
Desormais, Ileana (4)
Barbato, Emanuele (4)
James, Stefan K, 196 ... (4)
Halvorsen, Sigrun (4)
Steg, Philippe Gabri ... (4)
Mauri, Laura (4)
Byrne, Robert A. (4)
Vranckx, Pascal (4)
Bartelink, Marie-Lou ... (3)
Cohnert, Tina (3)
Debus, Sebastian (3)
Naylor, A Ross (3)
Röther, Joachim (3)
Venermo, Maarit (3)
Katus, Hugo A (3)
Knuuti, Juhani (3)
Hindricks, Gerhard (3)
Lancellotti, Patrizi ... (3)
James, Stefan, 1964- (3)
Huber, Kurt (3)
Crea, Filippo (3)
Jeppsson, Anders, 19 ... (3)
Petricevic, Mate (3)
visa färre...
Lärosäte
Uppsala universitet (14)
Göteborgs universitet (4)
Örebro universitet (1)
Linnéuniversitetet (1)
Karolinska Institutet (1)
Språk
Engelska (18)
Polska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (14)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy